Back to Search
STEPHEN JONES, M.D.
M.D.
Internal Medicine Physician
NPI: 1962530733Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
K2047(TX)
Research & Publications (20)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PMID 19204201·J Clin Oncol·2009
3-trial
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
PMID 19073509·Clin Breast Cancer·2008
4-observational
Considerations in treatment choice for metastatic breast cancer.
PMID 18224392·Breast Cancer·2008
8-other
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
PMID 17947724·J Clin Oncol·2007
4-observational
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
PMID 16595025·Clin Breast Cancer·2006
4-observational
Direct admission to cardiology for patients hospitalized for atrial fibrillation reduces length of stay and increases guideline adherence.
PMID 16808143·Mil Med·2006
8-other
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
PMID 17135639·J Clin Oncol·2006
3-trial
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
PMID 16110015·J Clin Oncol·2005
3-trial
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
PMID 15865850·Clin Breast Cancer·2005
4-observational
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
PMID 14613022·Semin Oncol·2003
6-review
Antiaromatase agents: evolving role in adjuvant therapy.
PMID 12020394·Clin Breast Cancer·2002
6-review
A new estrogen receptor antagonist--an overview of available data.
PMID 12353819·Breast Cancer Res Treat·2002
6-review
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
PMID 12123539·Clin Breast Cancer·2002
3-trial
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
PMID 11899353·Clin Breast Cancer·2001
8-other
Use of iodixanol self-generated density gradients to enrich for viable urothelial cells from nonneurogenic and neurogenic bladder tissue.
PMID 19351240·Tissue Eng Part C Methods·2010
8-other
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
PMID 19395187·Int J Radiat Oncol Biol Phys·2010
4-observational
Do we need multiple models of auditory verbal hallucinations? Examining the phenomenological fit of cognitive and neurological models.
PMID 18820262·Schizophr Bull·2010
6-review
Exploring the utility of an estimation procedure to reveal drug use among arrestees: implications for service delivery.
PMID 19130249·J Behav Health Serv Res·2010
8-other
Myristoylated alanine-rich C-kinase substrate (MARCKS) protein regulation of human neutrophil migration.
PMID 19574534·Am J Respir Cell Mol Biol·2010
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3214 SANDSTONE CT
PEARLAND, TX 77584 - Phone
- (713) 545-8480
Quick Facts
- NPI
- 1962530733
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile